Venmax Drugs and Pharmaceuticals Limited (BOM:531015)
India flag India · Delayed Price · Currency is INR
22.94
-1.06 (-4.42%)
At close: Jun 1, 2026

BOM:531015 Income Statement

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
80.258.07---
Revenue Growth (YoY)
894.04%----
Cost of Revenue
72.817.950.1--
Gross Profit
7.440.12-0.1--
Selling, General & Admin
1.970.470.230.30.19
Other Operating Expenses
4.2610.070.731.551.08
Operating Expenses
6.2710.61.021.941.36
Operating Income
1.16-10.48-1.12-1.94-1.36
Other Non Operating Income (Expenses)
1.6110.521.994.1919.83
EBT Excluding Unusual Items
2.770.050.872.2618.47
Asset Writedown
--0.19---
Pretax Income
2.77-0.140.872.2618.47
Income Tax Expense
0.29-0.040.2200
Net Income
2.48-0.110.652.2618.46
Net Income to Common
2.48-0.110.652.2618.46
Net Income Growth
---71.41%-87.78%-
Shares Outstanding (Basic)
125555
Shares Outstanding (Diluted)
125555
Shares Change (YoY)
125.60%---0.00%
EPS (Basic)
0.21-0.020.120.433.52
EPS (Diluted)
0.21-0.020.120.433.52
EPS Growth
---72.09%-87.78%-
Free Cash Flow
-109.96-22.90.02-0.0319.05
Free Cash Flow Per Share
-9.30-4.370.00-0.013.64
Gross Margin
9.26%1.52%---
Operating Margin
1.45%-129.77%---
Profit Margin
3.09%-1.30%---
Free Cash Flow Margin
-137.03%-283.69%---
EBITDA
1.2-10.41-1.05-1.86-1.27
EBITDA Margin
1.50%-128.97%---
D&A For EBITDA
0.040.060.070.080.09
EBIT
1.16-10.48-1.12-1.94-1.36
EBIT Margin
1.45%-129.77%---
Effective Tax Rate
10.37%-25.74%0.04%0.02%
Revenue as Reported
81.8518.611.994.1919.83
Advertising Expenses
-0.07---